Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 25 yuan [2][8]. Core Insights - The company is gradually overcoming the impact of centralized procurement, with business expansion accelerating. The revenue for the first three quarters of 2025 was 258 million yuan, a decrease of 19.73% year-on-year, while the net profit attributable to shareholders was 6 million yuan, down 76.33% [2][8]. - In Q3 2025, the revenue was 99 million yuan, a decline of 6.36% year-on-year, indicating a significant improvement compared to the first half of the year [2][8]. - The company has completed the integration of its subsidiary, Hebei Toukeng, and is entering the invasive fungal disease detection field, which fills a gap in its product offerings [8]. Financial Performance Summary - The total revenue forecast for 2024A is 437 million yuan, with a year-on-year growth rate of -19.5%. For 2025E, the revenue is expected to be 383 million yuan, with a growth rate of -12.4%. By 2026E, the revenue is projected to increase to 469 million yuan, reflecting a growth rate of 22.4% [4][9]. - The net profit attributable to shareholders is forecasted to be 34 million yuan in 2024A, dropping to 9 million yuan in 2025E, and then rising to 41 million yuan in 2026E, with a significant growth rate of 371.7% [4][9]. - The company maintains a high R&D expense ratio, with 15.52% for the first three quarters of 2025 and 17.16% for Q3 2025, indicating a commitment to innovation and product development [8]. Business Expansion and Product Development - The company is actively pursuing mergers and acquisitions to enhance its competitive edge in the tumor diagnosis field, including the acquisition of Kanglu Bio, a leader in the pathology diagnosis segment [8]. - New product lines in autoimmune, metabolic, hormone, and lung cancer methylation testing are contributing to revenue growth, alongside the integration of external acquisitions [8]. - The company has received medical device registration certificates for several new reagents, enhancing its product pipeline and market offerings [8].

证 券 研 究 报 告 科顺股份（300737）2025 年三季报点评 推荐（维持） 单季盈利能力持续承压，毛利率改善 目标价：6.10 元 事项： ❖ 公司发布 2025 年第三季度报告，前三季度实现营业收入 47.03 亿元，同比下 降 8.43%；归母 净利 润/ 扣非归 母净利 润 2009/-5774 万元，同 比下 降 84.08%/1623.35%。其中第三季度实现营业收入 14.83 亿元，同比下降 10.93%； 归母净利润/扣非归母净利润-2687/-4409 万元，同比下降 183.10%/16.79%。 评论： ❖ 风险提示：原材料价格大幅波动、地产超预期下行，应收账款恶化。 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 6,829 | 6,229 | 6,008 | 6,107 | | 同比增速(%) | -14.0% | -8.8% | -3.5% | 1.7% | | 归母净利润(百万) | 44 | 1 ...

Group 1: Credit Strategy and Market Overview - The credit bond market has experienced narrow fluctuations in yields, with a divergence in credit spreads. The market is currently influenced by geopolitical tensions and a pullback in US equities, leading to a weakened risk appetite for equities, while the bond market lacks a clear trading direction [1][8] - The excess spread of credit bond ETFs has risen significantly, indicating a rebound after a period of decline. This is attributed to the overall weak performance of credit bonds and the good liquidity of constituent bonds, which have seen a significant drop in valuation [1][9] - The current period is seen as a good window for accumulating interest-bearing assets, with the yield spread for 3-year bonds compressed below the lowest point expected for 2024, suggesting a low cost-performance ratio [1][12] Group 2: Long-term Credit Opportunities - There is a notable increase in the allocation of long-term credit bonds (10 years and above) by insurance and other products, indicating a trend towards extending duration for yield enhancement. Funds have shown a net buying trend for bonds with maturities of 5-7 years while slightly selling off 7-10 year bonds [2][21] - The yield for long-term credit bonds rated AA+ and above is currently in the range of 2.14%-2.66%, with credit spreads between 22-60 basis points, indicating sufficient spread protection [2][21] Group 3: Key Policies and Events - Jilin Province has met the conditions to exit the list of high-risk debt provinces, which is expected to open up new financing opportunities for regional development and bond issuance [3][27] - The support from Shenzhen Metro Group for Vanke's healthy development is crucial as Vanke faces significant operational challenges and debt repayment pressures [3][27] - CICC plans to merge with Dongxing Securities and Xinda Securities, which is expected to enhance market recognition and resource integration following regulatory support for brokerage mergers [3][27]

Investment Rating - The report indicates a positive investment outlook for the innovative drug sector, particularly focusing on RNA-targeted therapies for metabolic diseases [5][6]. Core Insights - The approval of the first APOC3 siRNA therapy for treating Familial Chylomicronemia Syndrome (FCS) marks a significant milestone in the RNA-targeted therapy landscape, showcasing the potential of these therapies in managing lipid disorders [17][28]. - RNA-targeted therapies, including small interfering RNA (siRNA) and antisense oligonucleotides (ASOs), are being developed to effectively lower triglyceride levels and improve patient compliance due to reduced dosing frequency [5][10]. - The report highlights ongoing clinical trials and the promising results of therapies like volanesorsen and olezarsen, which have shown significant reductions in triglyceride levels and lower incidence of acute pancreatitis in patients with FCS [17][28][34]. Summary by Sections Section 1: Focus on Innovative Drugs - The report emphasizes the rapid advancements in RNA-targeted therapies for metabolic diseases, particularly in the context of lipid management [5][6]. - Key developments include the approval of siRNA therapies that target APOC3 mRNA, which is crucial for regulating triglyceride levels in patients with FCS [10][17]. Section 2: Clinical Developments - The report details various therapies in clinical stages, including volanesorsen and olezarsen, which have received FDA approval and demonstrated efficacy in lowering triglyceride levels significantly [17][28]. - Clinical trial results indicate that patients treated with these therapies experienced substantial reductions in triglyceride levels compared to placebo groups, with olezarsen showing a 43.5% reduction at six months [28][34]. Section 3: Market Dynamics - The report outlines the competitive landscape, noting that several companies are advancing their RNA-targeted therapies through clinical trials, with a focus on improving patient outcomes and safety profiles [33][34]. - The potential market for these therapies is substantial, given the prevalence of metabolic diseases and the need for effective treatment options [5][6].

Investment Strategy - The report emphasizes that Xinjiang is benefiting from two major strategic shifts: moving from coastal economies to the Belt and Road Initiative, positioning Xinjiang as a frontier hub with geographical advantages. This shift is expected to enhance energy security and promote coal chemical industry development [7][8] - The report highlights the importance of coal chemical investment and state-owned enterprise reform as two main investment themes in Xinjiang. The external environment for coal chemical development is now favorable, with rising coal prices and a focus on resource allocation towards the western regions of China [7][8] Xinjiang Index Situation - The Xinjiang index is reported at 121.12, down 7.68% week-on-week. The Xinjiang coal chemical investment index is at 119.79, also down 7.67%, while the state-owned enterprise reform index stands at 123.83, down 7.08% [14] - The report lists the top gainers and losers in the market, with Guotong Co., Ltd. (002205.SZ) gaining 10.38% and Huijia Times (603101.SH) losing 15.07% [14] Key Data Tracking - Key prices in Xinjiang include Q5000 mixed coal at 100 CNY/ton, Q5200 mixed coal at 215 CNY/ton, and main coking coal at 700 CNY/ton. The price of methanol is reported at 1530 CNY/ton, with a price difference of -482.5 CNY/ton compared to East China [20] - In October 2025, the coal railway dispatch volume from state-owned key coal mines was 3.429 million tons, a year-on-year decrease of 4.14%, while the raw coal production in Xinjiang was 44.816 million tons, down 5.00% year-on-year [20] Key News and Company Announcements - Guanghui Logistics has signed new transportation agreements for 2026, with external customer orders exceeding 7 million tons, expected to generate a total contract value of approximately 700 million CNY. This positions the company to further solidify its market position [34] - The report mentions several ongoing coal chemical projects in Xinjiang, including a 1.2 million ton coal-to-LNG project and an 800,000 ton coal-to-olefins project, with significant investments aimed at enhancing local resource utilization [34][38] Overview of Target Companies - The report suggests focusing on companies involved in coal chemical projects in Xinjiang, including TBEA, Jiufeng Energy, Baofeng Energy, Guanghui Energy, and Hubei Yihua. Additionally, companies providing services to coal chemical projects and local state-owned enterprises are highlighted as potential investment opportunities [11][13]

债券研究 证 券 研 究 报 告 【债券周报】 存单周报（1117-1123）：月末关注银行负债 边际变化 债券周报 2025 年 11 月 23 日 华创证券研究所 证券分析师：周冠南 电话：010-66500886 邮箱：zhouguannan@hcyjs.com 执业编号：S0360517090002 证券分析师：宋琦 电话：010-63214665 邮箱：songqi@hcyjs.com 执业编号：S0360523080002 相关研究报告 《【华创固收】政策双周报（0530-0612）：买断 式逆回购前置操作，中美经贸磋商原则上达成框 架 》 2025-06-12 《【华创固收】评级披露仍较缓慢，关注权益轮 动向转债传导——可转债周报 20250609》 2025-06-09 《【华创固收】央行开始买债了吗？——债券周 报 20250608》 2025-06-08 《【华创固收】存单周报（0602-0608）：资金预 期有所缓和，关注存单配置价值》 2025-06-08 《【华创固收】关注震荡市场利差被动走阔的加 仓机会——信用周报 20250607》 2025-06-07 证监会审核华创证券投资咨 ...

Investment Rating - The report maintains a "Buy" rating for the automotive sector, anticipating a bottoming and upward trend in Q1 2026 [1]. Core Insights - The automotive sector is currently experiencing a cooling sentiment due to the impact of trade-in quotas, with October retail sales falling below expectations and November expected to perform moderately. The fourth quarter is also anticipated to underperform previous market expectations. However, the sector is expected to find a bottom and begin to rise in Q1 2026, presenting potential investment opportunities for the upcoming year [1][2]. Data Tracking - In early November, the discount rate for vehicles increased to 10.0%, up by 0.4 percentage points month-on-month and 1.5 percentage points year-on-year. The average discount amount rose by 23,103 yuan, with significant fluctuations among major brands [3]. - In October, new energy vehicle deliveries from leading companies showed a notable increase for BYD, which delivered 442,000 units, a month-on-month increase of 11.5% but a year-on-year decrease of 12.1%. Other companies like Leap Motor and Xpeng also reported significant year-on-year growth [3][20]. - Traditional automakers also saw growth in October, with Geely's sales reaching 307,000 units, a year-on-year increase of 35.0% and a month-on-month increase of 12.5% [3][23]. Industry News - The report highlights several key developments in the automotive industry, including the launch of new models and significant sales figures for new energy vehicles. For instance, from November 1 to 16, the retail sales of new energy vehicles reached 554,000 units, a year-on-year increase of 2% [30][31]. - The report also notes the introduction of advanced technologies in new models, such as the Deep Blue L06 and the Xiaopeng X9, which feature cutting-edge battery systems and autonomous driving capabilities [30][31].

证 券 研 究 报 告 华创农业 10 月白羽肉禽月报 毛鸡价格稳后上扬，鸡苗价格高位偏强 ❑ 毛鸡&鸡苗：毛鸡价格稳后上扬，鸡苗价格高位偏强。 父母代产能方面，2025 年 10 月协会样本点在产父母代存栏 2307 万套，同比 +2.5%，环比+0.7%；后备父母代种鸡平均存栏量 1532 万套，同比-6.8%，环比 -2.2%。10 月父母代鸡苗价格为 47.79 元/套，最新报价 25 年第 44 周数据为 45.97 元/套。 综合来看，鸡苗端环比上涨，毛鸡养殖端环比下降。10 月毛鸡养殖亏损 1.78 元/羽，环比盈利大幅下降；孵化场盈利 0.65 元/羽，环比盈利大幅扩张。 行业研究 农林牧渔 2025 年 11 月 23 日 推荐（维持） 华创证券研究所 证券分析师：张皓月 邮箱：zhanghaoyue@hcyjs.com 执业编号：S0360524070009 证券分析师：陈鹏 电话：021-20572579 邮箱：chenpeng1@hcyjs.com 执业编号：S0360521080002 行业基本数据 | | | 占比% | | --- | --- | --- | | 股票家数(只) ...

Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of 82.5 CNY [2][10]. Core Insights - The company's main operations continue to improve, with significant progress in innovative drug development. The third quarter of 2025 saw a revenue of 365 million CNY, a slight decrease of 1.55%, while the net profit attributable to shareholders increased by 18.52% to 83.59 million CNY, and the non-GAAP net profit rose by 27.85% to 69.19 million CNY [2][4]. Financial Performance - Total revenue projections for the company are as follows: 1,350 million CNY for 2024, 1,376 million CNY for 2025, 1,683 million CNY for 2026, and 2,106 million CNY for 2027, with year-on-year growth rates of 20.8%, 2.0%, 22.3%, and 25.2% respectively [5][11]. - The net profit attributable to shareholders is projected to be 238 million CNY in 2024, 277 million CNY in 2025, 339 million CNY in 2026, and 423 million CNY in 2027, reflecting growth rates of 5.1%, 16.2%, 22.5%, and 24.7% respectively [5][11]. - Earnings per share (EPS) are expected to increase from 1.35 CNY in 2024 to 2.40 CNY in 2027 [5][11]. Strategic Developments - The company has strategically increased its stake in Shanghai Chaoyang Pharmaceutical to 51.48%, enhancing its innovative drug pipeline and R&D capabilities in cutting-edge technologies such as molecular glue and PROTAC [4]. - The core product HP-001 (molecular glue) has shown promising safety in phase I clinical trials, with symptom improvement observed in patients, indicating "Best-in-Class" potential [4]. - The company has also received IND approval for its ADC drug YLSHO03 and is set to initiate phase I clinical trials [4]. Market Position - The company is positioned to benefit from the rapid release of new products and the management of generic drug R&D investments, despite facing challenges from the tenth batch of national procurement [10]. - The internationalization of its formulations has seen breakthroughs, with the naloxone nasal spray production line passing FDA inspections and awaiting final reports [10].

Investment Rating - The report maintains a "Recommendation" rating for the insurance industry, expecting the industry index to outperform the benchmark index by over 5% in the next 3-6 months [21]. Core Insights - The insurance index fell by 3.06% this week, outperforming the broader market by 0.71 percentage points. Major insurance stocks experienced declines, with notable drops from Sunshine Insurance (-4.8%) and China Pacific Insurance (-4.57%) [1]. - The China Actuarial Society released the "Guidelines for Expense Allocation of Life Insurance Products," which aims to enhance the scientific management of expenses within insurance companies and supports the implementation of the "reporting and operation integration" policy [2][4]. - As of the end of 2024, 34 insurance asset management companies managed a total of CNY 33.30 trillion, reflecting a year-on-year growth of 10.60% [2]. - The report highlights that 172 insurance companies have disclosed their solvency data for Q3 2025, with 14 achieving an AAA risk rating, while 4 companies fell below solvency standards [2]. Summary by Sections Market Performance - The insurance sector's performance was characterized by a 3.06% decline in the insurance index, with individual stocks like China Life and Ping An also showing significant decreases [1]. Regulatory Developments - The newly released guidelines categorize life insurance business expenses into variable and fixed costs, specifying which expenses should not be allocated and providing methods for expense allocation [4]. Financial Data - The total market capitalization of the insurance sector is CNY 32,109.56 billion, with a circulating market value of CNY 22,103.29 billion [6]. Valuation Metrics - The report provides PEV valuations for major life insurance companies, with China Life at 0.83x and Ping An at 0.71x [5]. - For property insurance, the PB valuations are noted, with China Re at 0.58x and PICC at 1.2x [10]. Investment Recommendations - Short-term recommendations focus on companies with performance elasticity, suggesting investments in New China Life, China Property & Casualty, and China Life. Long-term recommendations include China Pacific Insurance and China Ping An based on fundamental and valuation considerations [10].